An Update on Clinically Advanced PROTAC Degraders and Their Synthesis

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Proteolysis-targeting chimeras (PROTACs) represent a groundbreaking therapeutic strategy.
• PROTACs utilize the ubiquitin-proteasome system (UPS) for targeted protein degradation.
• Unlike traditional inhibitors, PROTACs offer enhanced specificity and can target previously undruggable proteins.

Purpose of the Study:

• To provide a comprehensive review of PROTAC technology.
• To detail current PROTAC targets and clinical development.
• To examine the design and synthesis of clinically advanced PROTAC molecules.

Main Methods:

• Literature review of PROTAC research and clinical trials.
• Analysis of PROTAC design principles and synthetic strategies.
• Overview of target protein degradation (TPD) mechanisms.

Main Results:

• PROTACs have demonstrated significant advancements in TPD over 20 years.
• Several PROTACs are nearing their first clinical approval.
• The review covers specific PROTAC targets and their clinical progress.

Conclusions:

• PROTACs are a revolutionary therapeutic modality with broad potential.
• The field is rapidly progressing towards clinical application.
• Understanding PROTAC design and synthesis is crucial for future drug development.